ANI Pharmaceuticals, Inc. (ANIP)
71.47
+0.41
(+0.58%)
USD |
NASDAQ |
Nov 13, 16:00
71.47
0.00 (0.00%)
After-Hours: 19:59
ANI Pharmaceuticals EPS Diluted (Quarterly) : 1.510 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.510 |
| June 30, 2026 | 1.052 |
| March 31, 2026 | 1.276 |
| December 31, 2025 | 1.172 |
| September 30, 2025 | 1.133 |
| June 30, 2025 | 0.3614 |
| March 31, 2025 | 0.6855 |
| December 31, 2024 | -0.5493 |
| September 30, 2024 | -1.266 |
| June 30, 2024 | -0.1394 |
| March 31, 2024 | 0.825 |
| December 31, 2023 | 0.039 |
| September 30, 2023 | 0.4985 |
| June 30, 2023 | 0.327 |
| March 31, 2023 | 0.0625 |
| December 31, 2022 | -0.2848 |
| September 30, 2022 | -0.5524 |
| June 30, 2022 | -0.9421 |
| March 31, 2022 | -1.272 |
| December 31, 2021 | -1.717 |
| September 30, 2021 | -0.3673 |
| June 30, 2021 | -1.167 |
| March 31, 2021 | 0.0072 |
| December 31, 2020 | -0.303 |
| September 30, 2020 | 0.0352 |
| Date | Value |
|---|---|
| June 30, 2020 | -1.031 |
| March 31, 2020 | -0.5891 |
| December 31, 2019 | -0.393 |
| September 30, 2019 | 0.3171 |
| June 30, 2019 | 0.5282 |
| March 31, 2019 | 0.0372 |
| December 31, 2018 | 0.4563 |
| September 30, 2018 | 0.4224 |
| June 30, 2018 | 0.2332 |
| March 31, 2018 | 0.1911 |
| December 31, 2017 | -0.83 |
| September 30, 2017 | 0.40 |
| June 30, 2017 | 0.23 |
| March 31, 2017 | 0.10 |
| December 31, 2016 | -0.09 |
| September 30, 2016 | 0.22 |
| June 30, 2016 | 0.10 |
| March 31, 2016 | 0.12 |
| December 31, 2015 | 0.25 |
| September 30, 2015 | 0.39 |
| June 30, 2015 | 0.31 |
| March 31, 2015 | 0.38 |
| December 31, 2014 | 1.82 |
| September 30, 2014 | 0.59 |
| June 30, 2014 | -0.21 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.221 |
| Supernus Pharmaceuticals, Inc. | 0.3516 |
| Ocular Therapeutix, Inc. | -0.4203 |
| Corcept Therapeutics, Inc. | 1.010 |
| Veru, Inc. | -0.3032 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 32.72M |
| Revenue (Quarterly) | 290.78M |
| Total Expenses (Quarterly) | 258.06M |
| Enterprise Value | 1.798B |
| Gross Profit Margin (Quarterly) | 54.92% |
| Profit Margin (Quarterly) | 11.25% |
| Earnings Yield | 7.01% |
| Operating Earnings Yield | 10.27% |
| Normalized Earnings Yield | 6.385 |